Sutro's con­tin­ued PhI da­ta read­outs in­di­cate im­prov­ing re­sponse in ovar­i­an can­cer. What's next?

Just a few months af­ter its last in­ter­im read­out, Sutro Bio­phar­ma $STRO is shar­ing more Phase I da­ta in a small, sin­gle-arm tri­al for its ovar­i­an can­cer pro­gram.

The San Fran­cis­co-based biotech an­nounced Thurs­day af­ter­noon that pa­tients with heavy pre­vi­ous treat­ment con­tin­ued to see im­prove­ments as they re­mained on the drug, with one in­di­vid­ual achiev­ing a com­plete re­sponse af­ter more than a year. With the new da­ta in hand, Sutro plans to be­gin a dose-ex­pan­sion co­hort in Jan­u­ary, which could be fol­lowed by an ac­cel­er­at­ed ap­proval ap­pli­ca­tion in the sec­ond half of 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER